| payload |
{"created_at":"2026-04-21T00:08:29.826 {"created_at":"2026-04-21T00:08:29.826903+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:6cb20f1d054bfb1d","evidence_event_ids":["evt_5dc5effd273a"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/why-nektar-therapeutics-stock-rocked-it-today","as_of":"2026-04-21T00:08:29.826903+00:00","canonical_url":"https://www.fool.com/investing/2026/04/20/why-nektar-therapeutics-stock-rocked-it-today/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/why-nektar-therapeutics-stock-rocked-it-today","article_chars":3294,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_74c495cef2c050f3","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/20/why-nektar-therapeutics-stock-rocked-it-today/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-21T21:30:29.514846+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsThe successful phase 2b trial followed a previous study that was affected by apparent enrollment errors.","fetched_title":"Why Nektar Therapeutics Stock Rocked it Today | Nasdaq","final_url":"https://www.nasdaq.com/articles/why-nektar-therapeutics-stock-rocked-it-today","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/why-nektar-therapeutics-stock-rocked-it-today","source_event_id":"evt_5dc5effd273a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"ab1c854ccf9bc5c3","kind":"unusual_volume","published_at":"2026-04-20T23:33:42+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["Monday","last year","April 20, 2026","December 17, 2004","April 15, 2005"],"entities":[{"asset_class":"equity","name":"Nektar Therapeutics","relevance":"high","symbol":"NKTR","type":"company"},{"asset_class":"other","name":"rezpegaldesleukin","relevance":"high","symbol":"","type":"drug"}],"event_type":"earnings","information_gaps":["Unusual volume ratio vs average is not provided in the text (baseline volume and volume_ratio are null).","No explicit confirmation is given that the volume spike was confirmed by news coverage beyond the described stock move; the article does not quantify volume.","The specific catalyst hypothesis for the volume delta is not explicitly stated; the only catalyst described is the Phase 2b trial results and prior enrollment-error context."],"key_facts":["The article says Nektar Therapeutics\u2019 shares \u201cthundered more than 18% higher\u201d on Monday.","Before market open, Nektar published results from a Phase 2b study of rezpegaldesleukin in patients with severe to very severe alopecia areata.","The Phase 2b trial found that patients who had already responded to the treatment grew more hair over time.","The article contrasts this with last year\u2019s news that the drug failed to demonstrate a statistically significant benefit in a 36-week treatment cycle.","The article states that last year\u2019s study had apparent enrollment errors, including that four patients dosed were not eligible for treatment.","The latest trial is described as lasting 52 weeks and as not including those individuals.","The article says Nektar plans to advance the drug into later-stage trials."],"numeric_claims":[{"label":"price_move_percent","value":"more than 18% higher"}],"primary_claim":"Nektar Therapeutics (NASDAQ: NKTR) shares increased by more than 18% after publishing promising Phase 2b trial results for rezpegaldesleukin in severe to very severe alopecia areata.","relevance_score":0.72,"sentiment":"positive","source_quality":"high","summary":"Nektar Therapeutics\u2019 stock rose sharply on Monday after the company published positive Phase 2b results for rezpegaldesleukin in severe alopecia areata. The article attributes the turnaround to improved trial outcomes versus a prior study that was affected by apparent enrollment errors.","topics":["clinical trial results","Phase 2b","alopecia areata","rezpegaldesleukin","stock price move","enrollment errors","pipeline advancement"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsThe successful phase 2b trial followed a previous study that was affected by apparent enrollment errors.","tickers":[],"title":"Why Nektar Therapeutics Stock Rocked it Today","url":"https://www.fool.com/investing/2026/04/20/why-nektar-therapeutics-stock-rocked-it-today/"}}... |